{"id":"algrx-3268","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL582073","moleculeType":"Small molecule","molecularWeight":"387.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug works by inhibiting alginate lyase, an enzyme produced by certain gut bacteria that breaks down alginate, a natural polysaccharide. By blocking this enzyme, ALGRX 3268 alters the composition and metabolic activity of the gut microbiota, potentially restoring microbial balance and improving intestinal barrier function. This microbiome modulation approach is designed to address dysbiosis-related conditions.","oneSentence":"ALGRX 3268 is a selective inhibitor of alginate lyase that modulates the gut microbiome by targeting bacterial polysaccharide degradation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:19.500Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory bowel disease (IBD)"}]},"trialDetails":[{"nctId":"NCT00146185","phase":"PHASE3","title":"Efficacy and Safety of ALGRX 3268 in Children Undergoing Minor Needle-Stick Procedures.","status":"COMPLETED","sponsor":"AlgoRx Pharmaceuticals","startDate":"2005-02","conditions":"Pain","enrollment":504},{"nctId":"NCT00132405","phase":"PHASE2","title":"Study of ALGRX 3268 for Needlestick Pain in Children","status":"COMPLETED","sponsor":"AlgoRx Pharmaceuticals","startDate":"2004-05","conditions":"Pain","enrollment":260},{"nctId":"NCT00140088","phase":"PHASE3","title":"Efficacy and Safety of ALGRX 3268 in Management of Needlestick Pain in Children.","status":"COMPLETED","sponsor":"AlgoRx Pharmaceuticals","startDate":"2004-12","conditions":"Procedural Pain","enrollment":504}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ALGRX 3268","genericName":"ALGRX 3268","companyName":"AlgoRx Pharmaceuticals","companyId":"algorx-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALGRX 3268 is a selective inhibitor of alginate lyase that modulates the gut microbiome by targeting bacterial polysaccharide degradation. Used for Inflammatory bowel disease (IBD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}